



Final Appraisal Recommendation

Advice number: 3812 – December 2012

Bortezomib (Velcade®) 3.5 mg subcutaneous injection

Limited submission by Janssen-Cilag Ltd

Recommendation of the All Wales Medicines Strategy Group

Bortezomib (Velcade®) 3.5 mg subcutaneous injection is recommended as an option for use within NHS Wales:

- **for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation;**
- **in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.**

Additional note(s):

- AWMSG is of the opinion that bortezomib (Velcade®) subcutaneous injection is appropriate for specialist only prescribing within NHS Wales for the above recommendation.
- Treatment with bortezomib (Velcade®) subcutaneous injection must be initiated and administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.
- For the indication under consideration, AWMSG is of the opinion that bortezomib (Velcade®) subcutaneous injection should be considered for use as an alternative to bortezomib (Velcade®) intravenous injection.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1254), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:
All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3812: Bortezomib (Velcade®) 3.5 mg subcutaneous injection. December 2012.